Journal Title
Title of Journal: Drugs Ther Perspect
|
Abbravation: Drugs & Therapy Perspectives
|
Publisher
Springer International Publishing
|
|
|
|
|
|
Authors: Sohita Dhillon Paul L McCormack
Publish Date: 2016/05/03
Volume: 32, Issue: 6, Pages: 232-237
Abstract
Eltrombopag Revolade® an orally active thrombopoietin receptor agonist fills an important formerly unmet clinical need in patients with severe aplastic anaemia refractory to prior immunosuppressive therapy In this patient population treatment with eltrombopag for 12–16 weeks produced a haematological response in at least one cell lineage in 40 of patients and extended treatment produced trilineage responses in nearly 41 of the responders In robust responders stable haematological counts were maintained after eltrombopag discontinuation Treatment with eltrombopag is generally well toleratedThe review updated from Drugs 2015755525–31 18 and was reviewed by E Angelucci Ospedale Oncologico di Riferimento Regionale Cagliari Italy Meral Beksac Ankara University Ankara Turkey R Desmond Tallaght Hospital Dublin Ireland P Scheinberg National Heart Lung and Blood Institute National Institutes of Health Bethesda MD USA During the peer review process the manufacturer of eltrombopag was also offered an opportunity to review this article Changes resulting from comments received were made on the basis of scientific and editorial merit
Keywords:
.
|
Other Papers In This Journal:
|